Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib and Brentuximab Vedotin in ALK-Positive ALCL
NCT02729961Phase 2Withdrawn
- Sponsor
- University of Washington
- Start
- Jan 2018
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceritinib in anaplastic large cell lymphoma (ALCL), sponsored by University of Washington. Primary endpoints: Complete Remission Rate at 3 years, Maximum Tolerated Dose at 6 weeks and 1 more. Planned start Jan 2018; status: withdrawn.
02
Drugs
ceritinib
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT02729961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02729961.